10-Q/A: Aspire Biopharma Faces Delisting Amid Mounting Losses

Aspire Biopharma Holdings, Inc. reported a substantial net loss and a 'going concern' warning for Q3 2025, while facing Nasdaq delisting for non-compliance with listing rules.

Summary

• Reported a net loss of $19,773,114 for the nine months ended September 30, 2025, a significant increase from $544,162 in the same period of 2024.
• Generated initial net revenue of $1,941 from nutraceutical products in the three months ended September 30, 2025, compared to no revenue in the prior year.
• Cash balance increased to $1,948,271 as of September 30, 2025, from $3,633 at December 31, 2024, primarily due to financing activities.
• Working capital deficit was $11,457,377 and accumulated deficit reached $22,550,347 as of September 30, 2025.
• Management has raised "substantial doubt" about the company's ability to continue as a going concern for the next twelve months.
• Received Nasdaq deficiency notices on April 16, 2025, for failing to maintain a minimum Market Value of Listed Securities ($50,000,000) and a minimum bid price ($1.00 per share), leading to a delisting threat.
• Successfully completed a clinical trial for its high-dose sublingual aspirin product in July 2025, with positive results demonstrating faster bioavailability and quicker anti-coagulant properties.
• Issued convertible notes totaling $3,750,000 (20% OID) in February 2025 and $9,687,500 (20% OID) in August 2025 to investors.
• Entered into an Equity Line of Credit (ELOC) agreement for up to $100,000,000 in common stock, but has not utilized it due to the floor price and current market conditions.
• Disclosure controls and procedures were deemed "not effective" by the CEO and CFO as of September 30, 2025, particularly for complex accounting areas like the company's recapitalization.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including a substantial net loss, significant accumulated and working capital deficits, and a 'going concern' warning. The Nasdaq delisting threat and ineffective disclosure controls highlight significant operational and governance weaknesses. While there is some positive progress in product development and initial revenue generation, these are overshadowed by the existential risks.

Positives

• Commenced generating revenue from nutraceutical products in Q3 2025, totaling $1,941.
• Successfully completed a clinical trial for its high-dose sublingual aspirin product in July 2025, with positive results showing faster bioavailability and quicker anti-coagulant effects compared to standard oral aspirin.
• Developed working formulations for sublingually administered melatonin, vitamins D, E, and K, and is developing a semaglutide product.
• Unveiled and began selling initial versions of caffeine products in Q3 2025 after successful trial runs and consumer/safety testing.
• Filed new patent applications for its aspirin formulation technology (expiring March 29, 2044, and October 1, 2045) and an omnibus patent for other drug classes and supplements.
• Secured significant financing through convertible notes, raising $3,000,000 (net of OID) in February 2025 and $7,750,000 (net of OID) in August 2025.

Negatives

• Reported a substantial net loss of $19,773,114 for the nine months ended September 30, 2025, significantly higher than $544,162 in the prior year.
• Accumulated deficit reached $22,550,347 and working capital deficit was $11,457,377 as of September 30, 2025.
• Received Nasdaq deficiency notices for failing to meet the minimum Market Value of Listed Securities ($50,000,000) and minimum bid price ($1.00 per share), leading to a delisting threat.
• Management has raised "substantial doubt" about the company's ability to continue as a going concern.
• Previously acquired Instaprin patent properties expired and the Instaprin trademark was cancelled due to the company's unawareness of filing deadlines.
• Disclosure controls and procedures were deemed "not effective" by the CEO and CFO, particularly for complex accounting areas.
• Significant increase in operating expenses, primarily due to $14,131,250 in stock-based compensation.
• High interest expense of $2,297,882 for the nine months ended September 30, 2025.
• The initial ELOC agreement for $100,000,000 has not been utilized for liquidity due to the floor price and current market conditions.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for the next twelve months due to its liquidity condition.
• The company faces delisting from Nasdaq due to failure to meet minimum Market Value of Listed Securities ($50,000,000) and minimum bid price ($1.00 per share) requirements, with no assurance of continued listing.
• Future capital requirements are significant, and there is no assurance that additional financing can be raised on acceptable terms or at all, which would materially and adversely affect the business.
• Previously acquired Instaprin patent properties expired and the Instaprin trademark was cancelled due to missed deadlines, potentially impacting the foundation of their new developments.
• The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and strong emphasis on proprietary products, with many competitors having substantially greater resources.
• Commercialization of aspirin products depends on obtaining FDA approval (505(b)(2) NDA), which is a a lengthy and uncertain process.
• The company relies on third-party contract manufacturers, and there is a risk that current capacity may be insufficient or alternative suppliers may not be secured.
• Disclosure controls and procedures were deemed "not effective," which could lead to errors or fraud in financial reporting.
• The convertible notes are convertible into a large number of common shares (up to 147,177,424 shares for the August 2025 Notes), posing a significant dilution risk to existing shareholders.
• A significant portion of debt and liabilities involves related parties, which can raise corporate governance concerns and potential conflicts of interest.

Future Outlook

The company expects to generate revenue by developing and marketing drugs and nutraceuticals using its sublingual delivery technology, potentially through licensing or collaboration agreements. Operating expenses, including general and administrative, research and development, and sales and marketing, are projected to increase with business growth and public company status. The company intends to raise additional capital through equity issuances to finance future opportunities. It plans to submit a 505(b)(2) NDA for its high-dose aspirin product in early 2026 and seek Fast Track designation in Q1 2026.

Management Comments

• "The Company intends to raise such capital through issuances of additional equity."
• "If additional financing is required from outside sources, the Company may not be able to raise it on terms acceptable to the Company or at all."
• "If the Company is unable to raise additional capital when desired, the Company's business, results of operations and financial condition would be materially and adversely affected."
• "Management has determined that the Company's liquidity condition raises substantial doubt about the Company's ability to continue as a going concern through twelve months from the date these condensed consolidated financial statements are available to be issued."
• "The Company maintains that it was not in default at any time since the Company filed Form NT 10-K and the required filings were made within the automatic extension period."
• "The Company believes that it is important to note that while the previously acquired intellectual property is dead or expired, Aspire has used these technologies and relationships as the foundation of its new patent applications and formulations."
• "Aspire's management had always intended to build upon the acquired intellectual property assets and enhance the patent protections and apply the technology to new patented products and classes of products."
• "The CEO and CFO concluded that our disclosure controls and procedures... were not effective including those controls surrounding complex accounting areas such as the accounting for the Company's recapitalization."

Industry Context

Aspire Biopharma operates in the highly competitive and rapidly advancing biopharmaceutical and supplements industry, focusing on novel sublingual delivery mechanisms. This niche aims to differentiate products by offering faster absorption and potentially reduced side effects (e.g., bypassing gastrointestinal issues with aspirin). The industry is characterized by significant R&D investment, regulatory hurdles (FDA approvals), and the need for substantial capital. The company's strategy to target known drugs and supplements with a new delivery method could allow for a faster path to market (e.g., 505(b)(2) pathway for aspirin) compared to developing entirely new chemical entities. However, it faces competition from established pharmaceutical giants and smaller innovative firms, all vying for market share and talent. The focus on nutraceuticals like melatonin and caffeine also places it in the broader, less regulated, but still competitive, health and wellness market.

Comparison to Industry Standards

• The company's failure to meet Nasdaq's minimum Market Value of Listed Securities ($50,000,000) and bid price ($1.00) requirements is a significant deviation from standard public company listing requirements, indicating severe non-compliance.
• The "substantial doubt" about the company's ability to continue as a going concern is a critical red flag, common in early-stage biopharma but signaling heightened financial risk compared to more established industry players.
• The R&D expenses of $823,879 for nine months, while increasing, are relatively modest for a biopharma company developing multiple product candidates, and the initial revenue of $1,941 is negligible compared to operating costs, which is typical for early-stage biopharma but highlights the long path to profitability.
• The expiration and cancellation of previously acquired Instaprin patents and trademarks due to missed deadlines reflect a significant lapse in intellectual property management, which is a critical asset for biopharma companies, contrasting sharply with industry best practices.
• The CEO and CFO's conclusion that disclosure controls and procedures are "not effective" is a serious governance issue, indicating a weakness in financial reporting that is below industry standards for public companies.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently undergoing a Nasdaq delisting process due to non-compliance with listing rules, having requested a hearing before the Nasdaq Hearings Panel.

Related Party Transactions

• Assumed $499,214 in liabilities from Loan and Transfer Agreements with New Sponsor, SSVK Associates, LLC, Apogee Pharma, and Jinal Sheth.
• Assumed $1,500,000 of debt under First and Second Subscription Agreements with New Sponsor, an affiliate, and investors.
• $353,679 owed to the Sponsor of PowerUp for administrative services and residual IPO proceeds.
• $1,000,000 payable to the Sponsor for a modified promissory note fee.
• $885,564 outstanding at September 30, 2025, from various non-convertible OID notes issued to related parties for working capital.
• Entered into a Securities Purchase Agreement with Cobra Alternative Capital Strategies, LLC, an entity controlled by Aspire's former Director of Investor Relations, Lance Friedman.
• Entered into a Blackstone Subscription Agreement with Blackstone Capital Advisors, Inc., an entity controlled by Lance Friedman.
• 1,662,500 shares issued to an affiliated company under a Corporate Advisory Agreement for advisory services related to the Reverse Acquisition.

Stakeholder Impact

• Shareholders face significant dilution risk from convertible notes (up to 147,177,424 shares for August 2025 Notes, plus other conversions).
• Nasdaq delisting would severely impact the liquidity and market value of shares for shareholders.
• The 'going concern' warning indicates a high risk of investment loss for shareholders.
• Employees may face uncertainty due to the 'going concern' warning and recent management changes.
• Customers could benefit from potential new sublingual products (aspirin, caffeine, melatonin, vitamins) offering new treatment options.
• Creditors face increased risk of repayment due to the 'going concern' warning, with some related-party notes subject to subordination agreements.
• Management is under significant pressure to secure financing, regain Nasdaq compliance, and improve internal controls.

Next Steps

• Present a plan to regain compliance with Nasdaq's MVLS Rule and Bid Price Rule at a hearing before the Nasdaq Hearings Panel.
• Conduct a search for a permanent Chief Executive Officer.
• Submit a section 505(b)(2) New Drug Application (NDA) for the high-dose aspirin product to the FDA in early 2026.
• Seek FDA 505(b)(2) Fast Track designation for the prescription strength high dose aspirin product in Q1 2026.
• Continue discussions with the FDA regarding the possibility of selling an OTC Monograph aspirin product with a modified warning.
• Potentially conduct a later clinical trial for aspirin in approximately 24 healthy human volunteers to evaluate pharmacodynamic effect on platelet inhibition.
• File a PCT application on October 1, 2025, claiming priority to U.S. Application No. 63/702,381.
• File an omnibus patent application in October 2025 to extend intellectual property rights to other classes of drugs and supplements.
• Conduct a limited pharmacokinetic study for the sublingually administered melatonin sleep-aid product.
• Explore licensing possibilities for the melatonin product.
• Patent the melatonin and vitamin formulations in due course.
• Continue developing a working formulation for a sublingual semaglutide product.
• Consider formulations for anti-nausea, anti-psychotic, ED drugs, and seizure medication.
• Raise additional financing through equity issuances.

Key Dates

Recommendation

The company faces severe existential threats including a 'going concern' warning, imminent Nasdaq delisting, and acknowledged 'not effective' disclosure controls. While there is some positive R&D progress, the financial instability, massive losses, and significant dilution risk from convertible debt far outweigh any potential upside in the near to medium term. The company's ability to raise future capital is uncertain, and its current operational and governance issues present an unacceptable level of risk for investors.

Keywords

Biopharmaceutical, Sublingual delivery, Aspirin, Caffeine, Melatonin, Drug development, SEC filing, 10-Q/A, Nasdaq delisting, Going concern, Convertible notes, Clinical trials, Pharmaceuticals, Nutraceuticals, Patent application, Biotech, ASBP